No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
NBIX250117C145000
- 1.50
- -0.10-6.25%
15min DelayClose Dec 20 16:00 ET
1.54High1.50Low
1.53Open1.60Pre Close109 Volume114 Open Interest145.00Strike Price16.75KTurnover27.32%IV8.18%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry1.50Extrinsic Value100Contract SizeAmericanOptions Type0.1920Delta0.0280Gamma135.42Leverage Ratio-0.0555Theta0.0174Rho26.00Eff Leverage0.0975Vega
Intraday
- 5D
- Daily
News
Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $160
Wedbush Raises Price Target on Neurocrine Biosciences to $154 From $148, Keeps Outperform Rating
Barclays Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165
Express News | Neurocrine Biosciences Inc : Jefferies Raises Target Price to $168 From $158
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Needham Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating